American Biotech company Moderna said it would on Monday submit its Covid-19 vaccine candidate for emergency regulatory approval in the United States and the European Union after preliminary analysis of late-stage testing showed an efficacy rate of 94%.
Moderna enlisted 30,000 participants in its Phase 3 clinical trial for the mRNA vaccine, including 196 cases of Covid-19, 30 of which were severe. The primary goal of the shot is to prevent Covid-19 symptoms. EFE-EPA
int/jt
